Yan M[au] - Search Results

Year	Number of Results
1960	1
1981	1
1982	1
1984	3
1985	1
1986	2
1987	3
1988	3
1989	1
1990	5
1991	6
1992	2
1993	7
1994	14
1995	8
1996	10
1997	7
1998	18
1999	14
2000	24
2001	23
2002	28
2003	35
2004	55
2005	81
2006	103
2007	129
2008	139
2009	154
2010	160
2011	179
2012	214
2013	286
2014	276
2015	360
2016	374
2017	375
2018	387
2019	506
2020	578
2021	751
2022	441

1

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Tilly H, et al. Among authors: yan m. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904799 Clinical Trial.

2

Chronic Kidney Disease: Strategies to Retard Progression.

Yan MT, Chao CT, Lin SH. Yan MT, et al. Int J Mol Sci. 2021 Sep 18;22(18):10084. doi: 10.3390/ijms221810084. Int J Mol Sci. 2021. PMID: 34576247 Free PMC article. Review.

3

Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.

Qing J, Ren Y, Zhang Y, Yan M, Zhang H, Wu D, Ma Y, Chen Y, Huang X, Wu Q, Mazhar M, Wang L, Liu J, Ding BS, Cao Z. Qing J, et al. Among authors: yan m. J Hepatol. 2022 Feb;76(2):394-406. doi: 10.1016/j.jhep.2021.09.032. Epub 2021 Oct 11. J Hepatol. 2022. PMID: 34648896

4

The alternative activity of nuclear PHGDH contributes to tumour growth under nutrient stress.

Ma C, Zheng K, Jiang K, Zhao Q, Sha N, Wang W, Yan M, Chen T, Zhao Y, Jiang Y. Ma C, et al. Among authors: yan m. Nat Metab. 2021 Oct;3(10):1357-1371. doi: 10.1038/s42255-021-00456-x. Epub 2021 Oct 18. Nat Metab. 2021. PMID: 34663976

5

ZNF382 controls mouse neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons.

Ma L, Yu L, Jiang BC, Wang J, Guo X, Huang Y, Ren J, Sun N, Gao DS, Ding H, Lu J, Zhou H, Zou L, Gao Y, Wang L, Sun K, Ming Y, Meng Z, Tao YX, Yan M. Ma L, et al. Among authors: yan m. J Exp Med. 2021 Dec 6;218(12):e20210920. doi: 10.1084/jem.20210920. Epub 2021 Nov 11. J Exp Med. 2021. PMID: 34762123 Free PMC article.

6

Interaction between macrophages and ferroptosis.

Yang Y, Wang Y, Guo L, Gao W, Tang TL, Yan M. Yang Y, et al. Among authors: yan m. Cell Death Dis. 2022 Apr 16;13(4):355. doi: 10.1038/s41419-022-04775-z. Cell Death Dis. 2022. PMID: 35429990 Free PMC article. Review.

7

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial.

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Yin Y, Shi Y, Pan Y, Wang Y, Xie W, Yan M, Liu Y, Yan P, Wu F, Zhu X, Zou J; DAWNA-1 Study Consortium. Xu B, et al. Among authors: yan m. Nat Med. 2021 Nov;27(11):1904-1909. doi: 10.1038/s41591-021-01562-9. Epub 2021 Nov 4. Nat Med. 2021. PMID: 34737452 Clinical Trial.

8

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Wu JY, et al. Among authors: yan ml. J Hepatocell Carcinoma. 2021 Oct 5;8:1233-1240. doi: 10.2147/JHC.S332420. eCollection 2021. J Hepatocell Carcinoma. 2021. PMID: 34676181 Free PMC article.

9

Sec13 promotes oligodendrocyte differentiation and myelin repair through autocrine pleiotrophin signaling.

Liu Z, Yan M, Lei W, Jiang R, Dai W, Chen J, Wang C, Li L, Wu M, Nian X, Li D, Sun D, Lv X, Wang C, Xie C, Yao L, Wu C, Hu J, Xiao N, Mo W, Wang Z, Zhang L. Liu Z, et al. Among authors: yan m. J Clin Invest. 2022 Apr 1;132(7):e155096. doi: 10.1172/JCI155096. J Clin Invest. 2022. PMID: 35143418 Free PMC article.

10

First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.

Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X. Zhang J, et al. Among authors: yan m. Clin Cancer Res. 2022 Feb 15;28(4):618-628. doi: 10.1158/1078-0432.CCR-21-2827. Clin Cancer Res. 2022. PMID: 34844975 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results